Experts have warned that the Omicron variant of coronavirus "poses a greater risk" to people with blood cancer. Meanwhile, experts from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust are examining the effects of a fourth booster dose in blood cancer patients.
They are currently examining antibody levels in blood cancer patients which help to protect the body by identifying and attacking viruses - the team is focusing on Omicron-protecting antibodies, reports Wales Online. Read more: Tory MP says Boris Johnson was 'ambushed with a cake' over party claims While patients with solid tumours generate normal amounts of antibodies, those with blood cancer who have received three doses of the Covid-19 vaccine produce them less frequently.
According to the study, only 56 per cent of those with blood cancer generated neutralising antibodies. This means after receiving three doses of the vaccine, 44 per cent of patients with blood cancer did not generate antibodies that could protect against Omicron.
The researchers note that antibodies are not the only line of defence with other parts of the immune system offering protection.
Read more on manchestereveningnews.co.uk